Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

The Akt inhibitor ISC-4 activates prostate apoptosis response protein-4 and reduces colon tumor growth in a nude mouse model.

Sharma AK, Kline CL, Berg A, Amin S, Irby RB.

Clin Cancer Res. 2011 Jul 1;17(13):4474-83. doi: 10.1158/1078-0432.CCR-10-2370. Epub 2011 May 9.

2.

The Akt inhibitor ISC-4 synergizes with cetuximab in 5-FU-resistant colon cancer.

Allen JE, Gallant JN, Dicker DT, Amin S, Irby RB, Sharma AK, El-Deiry WS.

PLoS One. 2013;8(3):e59380. doi: 10.1371/journal.pone.0059380. Epub 2013 Mar 12. Erratum in: PLoS One. 2013;8(11). doi:10.1371/annotation/aaa12360-0c90-42c3-bc43-d00022b68b81.

3.
4.

Prostate apoptosis response protein 4 sensitizes human colon cancer cells to chemotherapeutic 5-FU through mediation of an NF kappaB and microRNA network.

Wang BD, Kline CL, Pastor DM, Olson TL, Frank B, Luu T, Sharma AK, Robertson G, Weirauch MT, Patierno SR, Stuart JM, Irby RB, Lee NH.

Mol Cancer. 2010 Apr 30;9:98. doi: 10.1186/1476-4598-9-98.

5.

Delivery of PAR-4 plasmid in vivo via nanoliposomes sensitizes colon tumor cells subcutaneously implanted into nude mice to 5-FU.

Kline CL, Shanmugavelandy SS, Kester M, Irby RB.

Cancer Biol Ther. 2009 Oct;8(19):1831-7.

PMID:
19729995
6.

Inhibition of AKT promotes FOXO3a-dependent apoptosis in prostate cancer.

Das TP, Suman S, Alatassi H, Ankem MK, Damodaran C.

Cell Death Dis. 2016 Feb 25;7:e2111. doi: 10.1038/cddis.2015.403.

7.

Rottlerin suppresses growth of human pancreatic tumors in nude mice, and pancreatic cancer cells isolated from Kras(G12D) mice.

Huang M, Tang SN, Upadhyay G, Marsh JL, Jackman CP, Srivastava RK, Shankar S.

Cancer Lett. 2014 Oct 10;353(1):32-40. doi: 10.1016/j.canlet.2014.06.021. Epub 2014 Jul 19.

PMID:
25050737
8.

Overexpression of Par-4 sensitizes TRAIL-induced apoptosis via inactivation of NF-kappaB and Akt signaling pathways in renal cancer cells.

Lee TJ, Jang JH, Noh HJ, Park EJ, Choi KS, Kwon TK.

J Cell Biochem. 2010 Apr 1;109(5):885-95. doi: 10.1002/jcb.22504.

PMID:
20127709
9.
10.

The quinoline imidoselenocarbamate EI201 blocks the AKT/mTOR pathway and targets cancer stem cells leading to a strong antitumor activity.

Ibáñez E, Agliano A, Prior C, Nguewa P, Redrado M, González-Zubeldia I, Plano D, Palop JA, Sanmartín C, Calvo A.

Curr Med Chem. 2012;19(18):3031-43.

PMID:
22455594
11.

Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.

Sui H, Shi C, Yan Z, Li H.

Drug Des Devel Ther. 2015 Jun 22;9:3183-90. doi: 10.2147/DDDT.S82035. eCollection 2015.

12.

Par-4 downregulation confers cisplatin resistance in pancreatic cancer cells via PI3K/Akt pathway-dependent EMT.

Tan J, You Y, Xu T, Yu P, Wu D, Deng H, Zhang Y, Bie P.

Toxicol Lett. 2014 Jan 3;224(1):7-15. doi: 10.1016/j.toxlet.2013.10.008. Epub 2013 Oct 19.

PMID:
24144893
13.

Nuclear Localization of DNAJB6 Is Associated With Survival of Patients With Esophageal Cancer and Reduces AKT Signaling and Proliferation of Cancer Cells.

Yu VZ, Wong VC, Dai W, Ko JM, Lam AK, Chan KW, Samant RS, Lung HL, Shuen WH, Law S, Chan YP, Lee NP, Tong DK, Law TT, Lee VH, Lung ML.

Gastroenterology. 2015 Dec;149(7):1825-1836.e5. doi: 10.1053/j.gastro.2015.08.025. Epub 2015 Aug 22.

PMID:
26302489
14.

BI-69A11 enhances susceptibility of colon cancer cells to mda-7/IL-24-induced growth inhibition by targeting Akt.

Pal I, Sarkar S, Rajput S, Dey KK, Chakraborty S, Dash R, Das SK, Sarkar D, Barile E, De SK, Pellecchia M, Fisher PB, Mandal M.

Br J Cancer. 2014 Jul 8;111(1):101-11. doi: 10.1038/bjc.2014.227. Epub 2014 Jun 3.

15.

Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines.

Adachi Y, Lee CT, Coffee K, Yamagata N, Ohm JE, Park KH, Dikov MM, Nadaf SR, Arteaga CL, Carbone DP.

Gastroenterology. 2002 Oct;123(4):1191-204.

PMID:
12360481
16.

Cacalol, a natural sesquiterpene, induces apoptosis in breast cancer cells by modulating Akt-SREBP-FAS signaling pathway.

Liu W, Furuta E, Shindo K, Watabe M, Xing F, Pandey PR, Okuda H, Pai SK, Murphy LL, Cao D, Mo YY, Kobayashi A, Iiizumi M, Fukuda K, Xia B, Watabe K.

Breast Cancer Res Treat. 2011 Jul;128(1):57-68. doi: 10.1007/s10549-010-1076-8. Epub 2010 Jul 28.

PMID:
20665104
17.

Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.

Diaz RJ, Golbourn B, Faria C, Picard D, Shih D, Raynaud D, Leadly M, MacKenzie D, Bryant M, Bebenek M, Smith CA, Taylor MD, Huang A, Rutka JT.

Oncotarget. 2015 Feb 20;6(5):3359-74.

18.

Tirucallic acids are novel pleckstrin homology domain-dependent Akt inhibitors inducing apoptosis in prostate cancer cells.

Estrada AC, Syrovets T, Pitterle K, Lunov O, Büchele B, Schimana-Pfeifer J, Schmidt T, Morad SA, Simmet T.

Mol Pharmacol. 2010 Mar;77(3):378-87. doi: 10.1124/mol.109.060475. Epub 2009 Dec 16.

19.

DC120, a novel and potent inhibitor of AKT kinase, induces tumor cell apoptosis and suppresses tumor growth.

Deng R, Yang F, Chang SH, Tang J, Qin J, Feng GK, Ding K, Zhu XF.

Mol Pharmacol. 2012 Aug;82(2):189-98. doi: 10.1124/mol.111.077271. Epub 2012 May 2.

20.

KIT Signaling Promotes Growth of Colon Xenograft Tumors in Mice and Is Up-Regulated in a Subset of Human Colon Cancers.

Chen EC, Karl TA, Kalisky T, Gupta SK, O'Brien CA, Longacre TA, van de Rijn M, Quake SR, Clarke MF, Rothenberg ME.

Gastroenterology. 2015 Sep;149(3):705-17.e2. doi: 10.1053/j.gastro.2015.05.042. Epub 2015 May 28.

Supplemental Content

Support Center